 |
|
|
| |
Long-acting antiretroviral drugs / Marta Boffito MD
|
| |
| |
EACS 2019 Nov 8-11 Basel
Download the PDF here
Marta Boffito MD, PhD, FRCP
Clinical Research Lead, Clinical Research Facility
Consultant Physician and HIV Service Director
Chelsea and Westminster Hospital
London, UK
Reader, Imperial College London
London, UK
EACS - Outcomes for Women in Phase 3 Trials of Long-Acting Cabotegravir + Rilpivirine: Pooled ATLAS and FLAIR Week 48 Results - (11/08/19)
IDWeek Oct 2019
PERCEPTIONS OF AND PREFERENCES FOR ORAL OR LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT REGIMENS IN THE UNITED STATES AND CANADA - (10/24/19)
Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies - (10/8/19)
every 2 months.......
there will be a window to come in for injection to prevent missed dose that could be an issue, patient can come into clinic a few days before the scheduled time to prevent missed dose, or likely 1 week after scheduled dose will be ok.
ECLAIR: Phase 2A Safety and PK Study of Cabotegravir LA in HIV-Uninfected Men.......Long-Acting Cabotegravir Data Suggest PrEP Injections Every 8 Week
French Studies Find Eagerness for Long-Term Injectables--With Key Cautions - Mark Mascolini (11/06/19)
IAS - Patient Views on Long-Acting HIV Treatment: Cabotegravir + Rilpivirine as Maintenance Therapy (ATLAS 48-Week Results)
ID Week - PERCEPTIONS OF AND PREFERENCES FOR ORAL OR LONG-ACTING INJECTABLE ANTIRETROVIRAL TREATMENT REGIMENS IN THE UNITED STATES AND CANADA
Qualitative Thematic Analysis of Social Media Data to Assess Perceptions of Route of Administration for Antiretroviral Treatment Among People Living With HIV
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain
Transgender Women's Concerns and Preferences on Potential Future Long-Acting Biomedical HIV Prevention Strategies: The Case of Injections and Implanted Medication Delivery Devices (IMDDs)
This study conducted four focus groups with N = 18 transgender women in New York City to understand their concerns and preferences on long-acting PrEP injections and IMDDs. Findings showed that participants were overwhelmingly positive about long-acting HIV prevention strategies, though they had some apprehensions. Overall, participants felt that injections and IMDDs could help address adherence challenges, and that transgender-specific needs should be addressed during clinical trials. Also, there were concerns related to injection or IMDD logistics, concerns about injections' or IMDDs' presence in the body, and familiarity with these products affected participants' opinions on them. Findings from this work can be used to inform protocols, measures, materials, and adherence interventions in future initiatives for transgender women using PrEP injections or IMDDs.
|
| |
|
|
|
|
|
